Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 6/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.32 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.31 |
| ▸ | CASP6 | P55212 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17977068 | 0.81 | ACE (0.31) | — | |
| SCHEMBL8779711 | 0.79 | CYP3A4 (0.33) | — | |
| SCHEMBL21946000 | 0.77 | NOTUM (0.33) | NOTUMCASP6MAPK1 | |
| SCHEMBL8379231 | 0.77 | PIK3CD (0.41) | NOTUMMAPK1 | |
| SCHEMBL10371339 | 0.72 | ROCK2 (0.32) | CHRNB2CHRNA4ROCK2 | |
| SCHEMBL20931143 | 0.69 | — | — | |
| SCHEMBL5638082 | 0.67 | CYP3A4 (0.42) | NOTUM | |
| SCHEMBL13751309 | 0.65 | USP2 (0.36) | NOTUM | |
| SCHEMBL4335919 | 0.64 | NOTUM (0.39) | NOTUMMAPK1 | |
| SCHEMBL3123660 | 0.64 | NOTUM (0.39) | NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240116921-A1 | LACTAM (HETERO)ARYLFUSEDPYRIMIDINE DERIVATIVES AS INHIBITORS OF ERBB2 | ENLIVEN INC. | 2024-04-11 | — | — | US | disclosed |
| EP-4267137-A1 | LACTAM (HETERO)ARYLFUSEDPYRIMIDINE DERIVATIVES AS INHIBITORS OF ERBB2 | Enliven Inc. (US) | 2023-11-01 | — | — | EP | disclosed |
| WO-2022140769-A1 | LACTAM (HETERO)ARYLFUSEDPYRIMIDINE DERIVATIVES AS INHIBITORS OF ERBB2 | ENLIVEN THERAPEUTICS, INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| WO-2022140769-A1 | LACTAM (HETERO)ARYLFUSEDPYRIMIDINE DERIVATIVES AS INHIBITORS OF ERBB2 | ENLIVEN THERAPEUTICS, INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| CN-1821226-A | Antipicornaviral compounds, their preparation and use | AGOURON PHARMA (US) | 2006-08-23 | — | — | CN | disclosed |
| US-20060046966-A1 | Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis | AGOURON PHARMACEUTICALS, INC. | 2006-03-02 | — | — | US | disclosed |
| US-6995142-B2 | Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis | AGOURON PHARMACEUTICALS, INC. (US) | 2006-02-07 | — | — | US | disclosed |
| US-6906198-B1 | Antipicornaviral compounds, their preparation and use | AGOURON PHARMACEUTICALS, INC. (US) | 2005-06-14 | — | — | US | disclosed |
| CN-1198838-C | Anti-small RNA virus compound and preparation method and application thereof | AGOURON PHARMA (US) | 2005-04-27 | — | — | CN | disclosed |
| US-20040072907-A1 | Antipicornaviral compounds, compositions containing them, and methods for their use | PETER DRAGOVICH S (US) | 2004-04-15 | — | — | US | disclosed |
| EP-1073672-B1 | ANTIPICORNAVIRAL COMPOUNDS, THEIR PREPARATION AND USE | AGOURON PHARMA (US) | 2003-08-27 | — | — | EP | disclosed |
| EP-1329457-A2 | Antipicornaviral compounds, their preparation and use | AGOURON PHARMACEUTICALS, INC. (US) | 2003-07-23 | — | — | EP | disclosed |
| US-20030130204-A1 | Antipicornaviral compounds and compositons, their pharmaceutical uses, and materials for their synthesis | DRAGOVICH PETER SCOTT (US) | 2003-07-10 | — | — | US | disclosed |
| US-6531452-B1 | Peptide-like and peptidomimetic compounds that inhibit enzymatic activity of picornaviral 3C proteases and inhibit picornavirus replication | AGOURON PHARMACEUTICALS, INC. | 2003-03-11 | — | — | US | disclosed |
| US-20020032237-A1 | Antipicornaviral compounds, compositions containing them, and methods for their use | DRAGOVICH PETER S (US) | 2002-03-14 | — | — | US | disclosed |
| US-6331554-B1 | PICORNAVIRUS PROTEASE INHIBITORS | AGOURON PHARMACEUTICALS, INC. | 2001-12-18 | — | — | US | disclosed |
| CN-1311793-A | Anti-small RNA virus compound and preparation method and application thereof | AGOURON PHARMA (US) | 2001-09-05 | — | — | CN | disclosed |
| EP-1073672-A1 | ANTIPICORNAVIRAL COMPOUNDS, THEIR PREPARATION AND USE | AGOURON PHARMACEUTICALS, INC. (US) | 2001-02-07 | — | — | EP | disclosed |
| US-6020371-A | VIRICIDES; PROTEASE INHIBITORS | AGOURON PHARMACEUTICALS, INC. (US) | 2000-02-01 | — | — | US | disclosed |
| WO-1999057135-A1 | ANTIPICORNAVIRAL COMPOUNDS, THEIR PREPARATION AND USE | AGOURON PHARMACEUTICALS, INC. (US) | 1999-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240116921-A1 | LACTAM (HETERO)ARYLFUSEDPYRIMIDINE DERIVATIVES AS INHIBITORS OF ERBB2 | ERBB2, FGFR2, ERBB3 | NOTUM 1486/4885CHRNB2 4062/4885CHRNA4 4669/4885 |
| US-20020032237-A1 | Antipicornaviral compounds, compositions containing them, and methods for their use | RNASEL, RNASE1, GTF3C3 | NOTUM 1338/4885CHRNB2 4871/4885CHRNA4 4878/4885 |
| US-20040072907-A1 | Antipicornaviral compounds, compositions containing them, and methods for their use | PCNA, ZC3HAV1, POLR1C | NOTUM 3599/4885CHRNB2 4694/4885CHRNA4 4444/4885 |
| US-20060046966-A1 | Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis | PRCP, RNPEP, SARNP | NOTUM 2316/4885CHRNB2 4871/4885CHRNA4 4884/4885 |
| US-20030130204-A1 | Antipicornaviral compounds and compositons, their pharmaceutical uses, and materials for their synthesis | SARNP, RNASE1, SERPINA3 | NOTUM 2062/4885CHRNB2 4853/4885CHRNA4 4877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.